The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Break on through to the other side: crossover in renal denervation trials

EuroIntervention 2021;17:e961-e962. DOI: 10.4244/EIJV17I12A161

1. Piedmont Heart Institute, Atlanta, GA, USA
Nearly a decade ago, Alberto Zanchetti, the former editor of the Journal of Hypertension, and colleagues, stated that over 245,000 patients included in 50 clinical trials were more than sufficient to conclude that what really matters is lowering blood pressure (BP), how BP is lowered is of minor importance1. Although intended as a reference to the varied classes of antihypertensive medications, could this statement now be expanded to include both drug- and device-based therapies? To date, five sham-controlled randomised trials have demonstrated clinically meaningful and statistically significant reductions in BP with renal denervation (RDN), both in the absence and presence of concomitant ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Recruitment for placebo-controlled trials of interventional procedures: a patient-centred approach